Adverse events3,255

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 3,255

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Phase I - TG4001 5x10e6 Pfu + Avelumab	2	3	4
other	Anaemia	Blood and lymphatic system disorders	Phase I - TG4001 5x10e7 Pfu + Avelumab	0	6	0
other	Anaemia	Blood and lymphatic system disorders	Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab	15	34	26
other	Anaemia	Blood and lymphatic system disorders	Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab	17	46	43
other	Anaemia	Blood and lymphatic system disorders	Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab	13	44	29
other	Anaemia	Blood and lymphatic system disorders	Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab	2	5	4
other	Anaemia	Blood and lymphatic system disorders	Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab	0	4	0
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase I - TG4001 5x10e6 Pfu + Avelumab	0	3	0
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase I - TG4001 5x10e7 Pfu + Avelumab	0	6	0
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab	1	34	1
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab	0	46	0
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab	0	44	0
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab	0	5	0
other	Antiphospholipid syndrome	Blood and lymphatic system disorders	Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab	0	4	0
other	Haematotoxicity	Blood and lymphatic system disorders	Phase I - TG4001 5x10e6 Pfu + Avelumab	1	3	1
other	Haematotoxicity	Blood and lymphatic system disorders	Phase I - TG4001 5x10e7 Pfu + Avelumab	0	6	0
other	Haematotoxicity	Blood and lymphatic system disorders	Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab	0	34	0
other	Haematotoxicity	Blood and lymphatic system disorders	Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab	0	46	0
other	Haematotoxicity	Blood and lymphatic system disorders	Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab	0	44	0
other	Haematotoxicity	Blood and lymphatic system disorders	Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab	0	5	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03260023/events

API reference For AI assistants

Adverse events3,255

Sources 3

Read this list from software.